Synapse - Howard Scher

Search Within

Howard Scher

Results (1133)

Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Results of the COU-AA-301 phase 3 randomized trial

Meeting Abstract

Ryan, C.; Li, J. H.; Kheoh, T.; Scher, H. I.; Molina, A.
Cancer Research (2012)

Fulltext@MSK | Save

Does the catalytic activity of prostate-specific antigen (PSA) or kallikrein-related peptidase 2 (hK2) secreted by novel transgenic mice models critically influence development of prostate cancer or release of PSA or hK2 in blood

Meeting Abstract

Braun, K.; Ulmert, D.; von Bodman, C.; Byers, A.; Mehta, D.; Johnson, L.; Wenske, S.; Hricik, T.; Heller, G.; Scher, H.; more...
Cancer Research (2012)

Fulltext@MSK | Save

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Ryan, C. J.; Smith, M. R.; de Bono, J. S.; Molina, A.; Logothetis, C.; De Souza, P. L.; Fizazi, K.; Mainwaring, P. N.; Rodriguez, J. M. P.; Ng, S.; more...
Journal of Clinical Oncology (2012)

Fulltext@MSK | Save

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: Potential for rapid monitoring of treatment responses

Journal Article

Ulmert, D.; Vickers, A. J.; Scher, H. I.; Becker, C.; Iversen, P.; Frankel, D.; Jensen, J. K.; Olesen, T. K.; Lilja, H.
Clinical Chemistry and Laboratory Medicine (2012)

Fulltext@MSK | Save

Considerations in the development of circulating tumor cell technology for clinical use

Journal Article

Parkinson, D. R.; Dracopoli, N.; Petty, B. G.; Compton, C.; Cristofanilli, M.; Deisseroth, A.; Hayes, D. F.; Kapke, G.; Kumar, P.; Lee, J. S. H.; more...
Journal of Translational Medicine (2012)

Fulltext@MSK | Save

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building

Journal Article

Sherer, E. A.; Sale, M. E.; Pollock, B. G.; Belani, C. P.; Egorin, M. J.; Ivy, P. S.; Lieberman, J. A.; Manuck, S. B.; Marder, S. R.; Muldoon, M. F.; more...
Journal of Pharmacokinetics and Pharmacodynamics (2012)

Fulltext@MSK | Save

A pilot study comparing the sensitivity of detecting prostate associated transcripts by adna test prostate assay to cell search in whole blood from patients with castration resistant prostate cancer

Meeting Abstract

Samoila, A.; Wan, M.; Anand, A.; Chuang, T.; Scher, H. I.; Fleisher, M.; Danila, D. C.
Journal of Molecular Diagnostics (2012)

Fulltext@MSK | Save

Enzalutamide in prostate cancer after chemotherapy - The authors reply

Journal Article

Scher, H. I.; de Bono, J. S.
New England Journal of Medicine (2012)

Fulltext@MSK | Save

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors

Journal Article

Mitsiades, N.; Sung, C. C.; Schultz, N.; Danila, D. C.; He, B.; Eedunuri, V. K.; Fleisher, M.; Sander, C.; Sawyers, C. L.; Scher, H. I.
Cancer Research (2012)

Fulltext@MSK | Save

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomised trial

Journal Article

Logothetis, C. J.; Basch, E.; Molina, A.; Fizazi, K.; North, S. A.; Chi, K. N.; Jones, R. J.; Goodman, O. B.; Mainwaring, P. N.; Sternberg, C. N.; more...
Lancet Oncology (2012)

Fulltext@MSK | Save